Related Experiment Video

Updated: Dec 7, 2025

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.6K

Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF

Kieran F Docherty1, Muthiah Vaduganathan2, Scott D Solomon2

  • 1British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom.

JACC. Heart Failure
|October 2, 2020
PubMed

Insights

Sacubitril/valsartan, a heart failure medication, significantly reduces cardiovascular death and hospitalizations compared to enalapril. This review explores its integration into treatment and future potential for heart failure patients.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), offers improved outcomes in heart failure with reduced ejection fraction (HFrEF).
  • The PARADIGM-HF trial established its superiority over enalapril, a standard angiotensin-converting enzyme inhibitor.

Purpose of the Study:

  • To review the current understanding of sacubitril/valsartan's effects in HFrEF.
  • To discuss the integration of neprilysin inhibitors into multidrug regimens.
  • To highlight future developments and potential new indications for sacubitril/valsartan.

Main Methods:

  • Review of existing literature and clinical trial data.
  • Analysis of the integration of ARNI therapy within renin-angiotensin aldosterone system (RAS) blockade.
  • Evidence-based approach to clinical integration.

Main Results:

  • Sacubitril/valsartan demonstrated significant reductions in cardiovascular death and heart failure hospitalizations.
  • Enhanced understanding of combining neprilysin inhibitors with RAS blockers.
  • Identification of practical strategies for clinical implementation.

Conclusions:

  • Sacubitril/valsartan is a key therapy for HFrEF, surpassing enalapril.
  • Further research and clinical experience are expanding its role.
  • Practical guidance is available for its integration into patient care.

Keywords:
heart failureneprilysin inhibitionsacubitril/valsartan

More Related Videos

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

24.1K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
722
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
122
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.1K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
661
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
372
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
610